2019
DOI: 10.2174/9781681083971119040007
|View full text |Cite
|
Sign up to set email alerts
|

Anti-Angiogenic Therapy for Retinal Diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
0
0
Order By: Relevance
“…Retinal neovascularization results in hemorrhage and retinal detachment. Currently, ranibizumab, aflibercept, and bevacizumab are administrated for neovessel formation in AMD [198]. Intravitreal injection of antiangiogenic agents impedes serious side effects [199].…”
Section: Antiangiogenic Peptidesmentioning
confidence: 99%
“…Retinal neovascularization results in hemorrhage and retinal detachment. Currently, ranibizumab, aflibercept, and bevacizumab are administrated for neovessel formation in AMD [198]. Intravitreal injection of antiangiogenic agents impedes serious side effects [199].…”
Section: Antiangiogenic Peptidesmentioning
confidence: 99%